Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Imugene ( (AU:IMU) ) has issued an announcement.
Imugene Limited has received support from the FDA to advance its azer-cel treatment into a Phase 3 registrational study, targeting patients with relapsed DLBCL after CAR-T therapy. The FDA’s endorsement of Imugene’s dual endpoint strategy and Chemistry Manufacturing Controls readiness signifies a significant opportunity for the company in a high-need setting, potentially enhancing its market position in the immune-oncology sector.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical-stage immune-oncology company focusing on developing innovative cancer therapies. The company is known for its work in advancing treatments for CD19-positive cancers, particularly through its azercabtagene zapreleucel (azer-cel) program.
YTD Price Performance: -74.56%
Average Trading Volume: 2,270,181
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$100.9M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.